Ufp Technologies (UFPT) Cash from Financing Activities (2010 - 2026)
Ufp Technologies (UFPT) posted Cash from Financing Activities of -$1.6 million for Q1 2026, up 85.12% on a QoQ basis from -$10.9 million in Q4 2025, and up 84.87% year-over-year from -$875767.9 in Q1 2025.
Ufp Technologies (UFPT) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Ufp Technologies' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$1.6 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 84.87% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.1 million (down 133.98% YoY) and the FY2025 annual result came in at -$58.2 million, down 138.16% from the prior year.
- Cash from Financing Activities was -$1.6 million for Q1 2026 at Ufp Technologies, up from -$10.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $176.8 million in Q3 2024 and bottomed at -$28.9 million in Q3 2022.
- A 5-year average of $2.2 million and a median of -$10.7 million in 2025 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 3127.1% in 2022, while the deepest fall reached 721350.0% in 2022.
- Ufp Technologies' Cash from Financing Activities stood at -$20.7 million in 2022, then soared by 45.74% to -$11.2 million in 2023, then slumped by 102.04% to -$22.7 million in 2024, then soared by 52.09% to -$10.9 million in 2025, then jumped by 85.12% to -$1.6 million in 2026.
- Business Quant data shows UFPT's Cash from Financing Activities at -$1.6 million in Q1 2026, -$10.9 million in Q4 2025, and -$17.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Ufp Technologies | 1.82 Bn | 1.80 Bn | 44.36 Mn | -1.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.62 Mn |
| Mar 31, 2026 | -1.62 Mn |
| Dec 31, 2025 | -10.88 Mn |
| Dec 31, 2025 | -10.88 Mn |
| Sep 30, 2025 | -17.49 Mn |
| Sep 30, 2025 | -17.49 Mn |
| Jun 30, 2025 | -19.08 Mn |
| Jun 30, 2025 | -19.08 Mn |
| Mar 31, 2025 | -10.70 Mn |
| Mar 31, 2025 | -10.70 Mn |
| Dec 31, 2024 | -22.72 Mn |
| Dec 31, 2024 | -22.72 Mn |
| Sep 30, 2024 | 176.78 Mn |
| Sep 30, 2024 | 176.78 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | -2.72 Mn |
| Mar 31, 2024 | -2.72 Mn |
| Dec 31, 2023 | -11.24 Mn |
| Dec 31, 2023 | -11.24 Mn |